AR029648A1 - El uso de un agonista de rar - Google Patents

El uso de un agonista de rar

Info

Publication number
AR029648A1
AR029648A1 ARP000105436A ARP000105436A AR029648A1 AR 029648 A1 AR029648 A1 AR 029648A1 AR P000105436 A ARP000105436 A AR P000105436A AR P000105436 A ARP000105436 A AR P000105436A AR 029648 A1 AR029648 A1 AR 029648A1
Authority
AR
Argentina
Prior art keywords
agonists
rar
rar agonist
raralfa
gamma
Prior art date
Application number
ARP000105436A
Other languages
English (en)
Inventor
Paula Nanette Belloni
Michael Klaus
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR029648A1 publication Critical patent/AR029648A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El uso de un agonista de RAR que es por lo menos selectivo para gamma y preservador de RARalfa para la fabricacion de medicamentos que contienen uno o más de tales agonistas para el tratamiento del enfisema o enfermedades pulmonares asociadas. El uso de agonistas de RAR que sean por lo menos selectivos para gamma y preservadores de RARalfa para la fabricacion de medicamentos que contienen uno o más de tales agonistas para el tratamiento de enfermedades asociadas con lesion alveolar. Agonistas RAR especialmente preferidos son los compuestos de Formula (1) y Formula (2).
ARP000105436A 1999-10-19 2000-10-17 El uso de un agonista de rar AR029648A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19

Publications (1)

Publication Number Publication Date
AR029648A1 true AR029648A1 (es) 2003-07-10

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105436A AR029648A1 (es) 1999-10-19 2000-10-17 El uso de un agonista de rar

Country Status (34)

Country Link
US (1) US6300350B1 (es)
EP (1) EP1225878B1 (es)
JP (2) JP4074458B2 (es)
KR (1) KR100485581B1 (es)
CN (1) CN1201730C (es)
AR (1) AR029648A1 (es)
AT (1) ATE344661T1 (es)
AU (1) AU777325B2 (es)
BR (1) BR0015225A (es)
CA (1) CA2387844C (es)
CY (1) CY1105941T1 (es)
CZ (1) CZ20021657A3 (es)
DE (1) DE60031790T2 (es)
DK (1) DK1225878T3 (es)
ES (1) ES2274810T3 (es)
HK (1) HK1051002A1 (es)
HR (1) HRP20020329A2 (es)
HU (1) HUP0203295A3 (es)
IL (1) IL149151A0 (es)
JO (1) JO2178B1 (es)
MA (1) MA26835A1 (es)
MX (1) MXPA02003843A (es)
MY (1) MY129001A (es)
NO (1) NO328738B1 (es)
NZ (1) NZ518118A (es)
PE (1) PE20010678A1 (es)
PL (1) PL357499A1 (es)
PT (1) PT1225878E (es)
RS (1) RS50165B (es)
RU (1) RU2257383C2 (es)
TR (1) TR200201071T2 (es)
TW (1) TWI288639B (es)
WO (1) WO2001030326A1 (es)
ZA (1) ZA200202576B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
RU2299877C2 (ru) * 2001-09-18 2007-05-27 Ф.Хоффманн-Ля Рош Аг Производные алкилмочевины, обладающие свойствами ретиноидных агонистов (i), фармацевтическая композиция и лекарственное средство
BR0212607A (pt) 2001-09-18 2004-08-17 Hoffmann La Roche Agonistas retinóides ii de uréia substituìda
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
DK1656026T3 (da) 2003-08-22 2014-07-14 Dupont Nutrition Biosci Aps Sammensætning, der omfatter et bakteriocin og et ekstrakt fra en plante fra læbeblomstfamilien
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
US20100076037A1 (en) * 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
NZ607547A (en) 2010-09-01 2015-06-26 Univ Jefferson Composition and method for muscle repair and regeneration
KR102055395B1 (ko) 2011-06-24 2019-12-12 쥐알아이 바이오,아이엔씨. 염증 질환의 예방 및 치료
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP2736332A4 (en) * 2011-07-29 2015-03-18 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
EP3428153A1 (en) 2012-12-17 2019-01-16 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
WO2014099676A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
WO2015026990A2 (en) 2013-08-20 2015-02-26 University Of Washington Through Its Center For Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydrolase
EP3039126B1 (en) 2013-08-26 2019-10-09 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618590B2 (en) 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
ES2270537T3 (es) * 1997-11-12 2007-04-01 F. Hoffmann-La Roche Ag Tratamiento de enfermedades inmunes mediadas por celulas t ayudantes de tipo 2.
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
WO2000061182A2 (en) 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist
AU4225500A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
JP3961827B2 (ja) * 1999-08-02 2007-08-22 エフ.ホフマン−ラ ロシュ アーゲー 新規な選択的レチノイドアゴニスト
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
BR0015225A (pt) 2002-07-16
CN1201730C (zh) 2005-05-18
TWI288639B (en) 2007-10-21
IL149151A0 (en) 2002-11-10
KR100485581B1 (ko) 2005-04-27
DK1225878T3 (da) 2007-03-05
PL357499A1 (en) 2004-07-26
HUP0203295A2 (hu) 2003-01-28
EP1225878B1 (en) 2006-11-08
CA2387844C (en) 2009-04-14
NO20021823L (no) 2002-04-18
YU29002A (sh) 2005-06-10
NZ518118A (en) 2004-02-27
CN1382042A (zh) 2002-11-27
DE60031790T2 (de) 2007-09-20
TR200201071T2 (tr) 2002-08-21
NO328738B1 (no) 2010-05-03
CY1105941T1 (el) 2011-04-06
ZA200202576B (en) 2003-09-23
MY129001A (en) 2007-03-30
JP4074458B2 (ja) 2008-04-09
KR20020043640A (ko) 2002-06-10
MA26835A1 (fr) 2004-12-20
EP1225878A1 (en) 2002-07-31
JO2178B1 (en) 2003-04-23
HK1051002A1 (en) 2003-07-18
RS50165B (sr) 2009-05-06
JP2003512418A (ja) 2003-04-02
JP4850791B2 (ja) 2012-01-11
ATE344661T1 (de) 2006-11-15
RU2257383C2 (ru) 2005-07-27
US6300350B1 (en) 2001-10-09
HUP0203295A3 (en) 2003-04-28
CZ20021657A3 (cs) 2002-10-16
PT1225878E (pt) 2007-01-31
JP2007302689A (ja) 2007-11-22
PE20010678A1 (es) 2001-07-04
ES2274810T3 (es) 2007-06-01
NO20021823D0 (no) 2002-04-18
AU777325B2 (en) 2004-10-14
DE60031790D1 (de) 2006-12-21
MXPA02003843A (es) 2002-09-30
WO2001030326A1 (en) 2001-05-03
CA2387844A1 (en) 2001-05-03
AU1137401A (en) 2001-05-08
HRP20020329A2 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
AR029648A1 (es) El uso de un agonista de rar
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
ES2093979T3 (es) Esteres nitricos de derivados del acido 2-(2,6-dihalofenilamino)fenilacetico y su procedimiento de preparacion.
ES2143122T3 (es) Sulfonimidamidas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
GT199700009AA (es) Terapia combinada para la osteoporosis
ES2133270T3 (es) Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna.
DE59400489D1 (de) Fungizide Wirkstoffkombinationen
ES2093734T3 (es) Combinaciones microbicidas de productos activos.
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
ES2063102T3 (es) Imidazoles para el tratamiento de la aterosclerosis.
ES2181766T3 (es) Analogos de delda 12,13-isotaxol, uso antineoplasico y composiciones farmaceuticas que los contienen.
DE60034778D1 (de) Stoppen, schützen und konservieren von organen
MX9201356A (es) Derivados de piperidina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
UY27208A1 (es) Una combinación que comprende combretastatina y agentes anticarcinógenos.
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
ES2067874T3 (es) Derivados de acetamida.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
DE3873603T2 (de) Zusammensetzung gegen coccidiosis.
ES2154002T3 (es) 2-naftoilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure